Ruggiero A, Fabbrocini G, Cinelli E, et al. - Findings demonstrate effectiveness and safety of anti-IL-23s as promising treatment choices for psoriasis in real-word-practice in elderly patients, and no significant difference was evident among these agents.

• This is a 40/44 weeks single-center retrospective study of patients (n=34; aged≥65 years) with moderate-to-severe plaque-psoriasis, who received guselkumab (n=20), risankizumab (n=8), or tildrakizumab (n=6).

• PASI90 and PASI100 were observed in 29.4% and 8.8% at week 4, and in 58.8% and 29.4% at week 28, respectively.

• In guselkumab and risankizumab groups, 71.4% reached PASI90 and 53.5% PASI100 at week 40-44.

• Treatment discontinuation occurred in four patients (11.7%), and there were no significant differences among groups.